Increased Intestinal eccDNA as a Biomarker in Inflammatory Bowel Disease

Overview

This study identifies significantly elevated levels of extrachromosomal circular DNA (eccDNA) in intestinal biopsies from patients with inflammatory bowel disease (IBD) compared to healthy controls. Notably, eccDNA levels correlate with disease activity in ulcerative colitis and reveal gene-specific patterns that may serve as novel biomarkers for IBD type and activity.

Background

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is characterized by chronic gastrointestinal inflammation with a relapsing-remitting course. Diagnosis relies on clinical and histological assessments, but current biomarkers are limited, and many patients exhibit suboptimal responses to therapy. Extrachromosomal circular DNA (eccDNA) is a semi-stable DNA structure implicated in cancer and inflammation, but its role in IBD has not been previously explored. Given the association of chronic inflammation with DNA damage, investigating eccDNA in IBD may provide insights into disease mechanisms and novel biomarkers.

Data Highlights

Key Findings

• Intestinal biopsies from IBD patients contain significantly elevated eccDNA levels compared to healthy controls.
• Active ulcerative colitis patients show higher eccDNA production than those in remission, indicating correlation with disease activity.
• Crohn’s disease patients also have increased eccDNA, though differences between active and inactive disease are less pronounced.
• Specific eccDNAs containing gene fragments such as NRG1 and ZPMF2 are enriched in IBD patients, suggesting disease-specific genic hotspots.
• Healthy controls exhibit a more random, stochastic pattern of eccDNA compared to the consistent patterns seen in IBD.

Clinical Implications

The identification of elevated and gene-specific eccDNA in IBD patients offers a promising avenue for developing novel biomarkers to improve disease diagnosis and monitoring. eccDNA profiling could aid in distinguishing disease type and activity, potentially guiding therapeutic decisions and predicting treatment response. Further validation may enable eccDNA-based assays to complement existing clinical assessments in IBD management.

Conclusion

This study reveals a distinct pattern of increased intestinal eccDNA associated with IBD and active disease states, highlighting eccDNA as a potential biomarker for disease type and activity. These findings open new perspectives for molecular diagnostics and personalized management in IBD.

References

1. Original Article 2024 -- Association of Increased Intestinal Extrachromosomal Circular DNA with Inflammatory Bowel Disease